Contineum Therapeutics Welcomes Sarah Boyce to Board

Contineum Therapeutics, Inc. Class A (CTNM) has provided an announcement.

Contineum Therapeutics, Inc. has appointed Sarah Boyce to its Board of Directors as a Class I director, effective June 24, 2024, with her term expiring at the 2025 annual meeting. Boyce, who brings extensive experience from her leadership roles at Avidity Biosciences and other pharmaceutical companies, will also chair the Board’s Nominating and Corporate Governance Committee. She replaces Lori Lyons-Williams in this role but will be compensated similarly to other non-employee directors and has no familial or material conflicts of interest with the company.

See more insights into CTNM stock on TipRanks’ Stock Analysis page.